Japan PPI inflation slips to 11-mth low in July
LOS ANGELES - Kairos Pharma Ltd. (NYSE American: KAPA), a biopharmaceutical company specializing in oncology therapeutics with a current market capitalization of $14.36 million, is progressing with clinical trials for its lead drug, ENV105, as detailed in a recent letter to shareholders by CEO John Yu, M.D. ENV105 is currently undergoing a Phase 2 trial for prostate cancer and a Phase 1 trial for a type of lung cancer known as EGFR-dependent non-small cell lung cancer.
The company has received a $876,000 grant from the Department of Defense to support a biomarker study for lung cancer patients responsive to ENV105, which is part of their efforts to identify patients who may benefit most from the drug. In addition to their partnership with Cedars Sinai Hospital, where both trials are being conducted, Kairos Pharma has expanded its prostate cancer trial sites to include the University of Utah and City of Hope.
Kairos Pharma aims to provide safety and interim efficacy results by the end of the second quarter of 2025. The company is also developing immune response compounds like KROS101, which have shown promise in increasing the killer T cell population while decreasing the suppressor Treg population in cancer treatment.
Despite economic challenges, Kairos Pharma maintains financial strength, with a healthy current ratio of 4.2 and more cash than debt on its balance sheet, supported by recent private placements and non-dilutive funding. According to InvestingPro data, analyst price targets range from $4 to $12, significantly above the current trading price. The company has significant analyst coverage from investment banks such as EF Hutton and HC Wainwright and will be participating in healthcare conferences hosted by D. Boral and HC Wainwright later this year. Unlock more insights and 7 additional ProTips with InvestingPro.
The CEO expressed optimism about the company’s robust intellectual property portfolio, which is expected to provide protection into the 2030s, and their research’s potential to address unmet medical needs in cancer and inflammation. While the stock has experienced a significant decline over the past three months, InvestingPro’s Fair Value analysis suggests the company may be undervalued at current levels.
This press release contains forward-looking statements and is based on current expectations and projections about future events. Actual outcomes may differ due to risks and uncertainties related to product research, development, and regulatory approval processes. The information is based on a press release statement from Kairos Pharma.
In other recent news, Kairos Pharma has received an $876,000 grant from the U.S. Department of Defense to support research on overcoming resistance to lung cancer treatment. This funding will aid studies at Cedars-Sinai Medical Center to identify biomarkers in non-small cell lung cancer patients who have developed resistance to osimertinib. Concurrently, Kairos Pharma’s leading asset, ENV-105, is undergoing clinical trials for both metastatic castration-resistant prostate cancer and non-small cell lung cancer. ENV-105 is an antibody targeting CD105, a protein linked to drug resistance in cancer. H.C. Wainwright has maintained a Buy rating on Kairos Pharma with a $12 price target, highlighting the potential of its oncology pipeline. The firm anticipates significant milestones, including interim Phase 2 data for prostate cancer in 2025. Additionally, Kairos has completed the safety lead-in phase of its Phase 2 trial for prostate cancer, with the study now progressing to the randomized phase. The trial is supported by a National Cancer Institute grant and focuses on validating biomarkers for effective treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.